2026 H1 -tulosraportti
9 päivää sitten
‧45 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 300 | - | - | ||
| 10 000 | - | - | ||
| 1 517 | - | - | ||
| 3 000 | - | - | ||
| 183 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 -tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 28.8. | ||
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·4 t sittenSome facts about the USA plan and AlphaOne Some things are being mixed up here. Thor has not announced that they are now going to build a new AlphaOne/AlphaTwo factory in the USA for approximately 1 billion NOK. The strategy Thor describes is much more flexible: The central upstream production can continue to be located at Herøya, while downstream production is established closer to customers and patients – among others in the USA. Thor itself writes that the platform can be expanded both through central production and decentralized production closer to the end markets. This makes good sense due to the properties of the isotopes. Th-228 can be produced at Herøya and used as a precursor for Pb-212, while Pb-212, with its short half-life, is advantageously produced closer to the place where it is to be used. Nor is it just a theory. Thor already has a five-year American agreement with RadioMedix, where Thor will supply Th-228 from 2026. RadioMedix specifically needs Th-228 as a precursor for the production of Pb-212 via their generator platform. The same model is seen with other customers. Telix, for example, will use Th-228 from Thor as a precursor for Pb-212 via their own generator and radiopharmacy infrastructure. Therefore, the 300 million NOK are also not presented as financing for a billion-dollar factory in the USA. The capital will, among other things, be used to build downstream Pb-212 capacity and commercial infrastructure in the USA, as well as feedstock and working capital. And regarding the claim of production problems: I cannot find any documentation for it. On the contrary, Thor states that AlphaOne was completed on time and on budget, commercial production has started, the first commercial delivery from AlphaOne has been completed, and production and customer deliveries are now to be gradually increased during ramp-up. This, of course, does not mean that Thor is without risk or will never need more capital. But there is a big difference between that and concluding that they now lack about a billion for an American AlphaTwo factory or have production problems. The actual strategy rather seems to be: produce the longer-lived precursor isotopes centrally and place the short-lived downstream production closer to the customers. In my opinion, this seems much more sensible both industrially and capital-wise.
·4 t sittenFinasavisenes' angle: https://e24.no/boers-og-finans/i/6qdy53/thor-medical-truffet-av-emisjonslynet https://www.dn.no/borskommentar/kunne-like-godt-satt-opp-plakat-i-vindu-verdiodeleggende-emisjon-kommer/2-1-2039399 ..That feeling. Buying shares at a price of seven kroner on a Wednesday, and then the share goes on sale at a price of 4.8 kroner the week after...It's always unfortunate when a stock goes down. But I believe the steps they are taking are crucial for future growth. There will probably be new rounds with a need for capital. So if one fears new share issues, TM is not the place to be. But that the company's communication could have been better, I absolutely believe. It is better to inform about growth plans and financing models, than to send some brokerage firms ahead of oneself as useful idiots. That being said, the growth this can generate outweighs the dilution, and that is probably the whole point. To make money. In April, the stock went from 5.5 and for a short while down to the top of the 3-range. It recovers as long as the company delivers on what they say.
·21 t sittenThor raised kr 300 mill. That is little. It is not Alpha Two or Alpha Global that are to be built, the gigantic factories will cost approximately kr 1 billion each. So here they will eventually need much more capital. But are they possibly building a US copy of Alpha One over there? I believe the stock price will continue as it is, as they produce far too little from Alpha One. At the Q presentation, the CEO states that they have only delivered th-228 to one customer. Problems with production, or ??Båtsjefen : It's all nonsense you're saying. Read my post and you will understand.
·1 päivä sittenDo people think that this is safe in the long term, and will rise higher, and is therefore a good investment?
I believe what one will primarily associate this company with in the short and long term is share issues..
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 H1 -tulosraportti
9 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenSome facts about the USA plan and AlphaOne Some things are being mixed up here. Thor has not announced that they are now going to build a new AlphaOne/AlphaTwo factory in the USA for approximately 1 billion NOK. The strategy Thor describes is much more flexible: The central upstream production can continue to be located at Herøya, while downstream production is established closer to customers and patients – among others in the USA. Thor itself writes that the platform can be expanded both through central production and decentralized production closer to the end markets. This makes good sense due to the properties of the isotopes. Th-228 can be produced at Herøya and used as a precursor for Pb-212, while Pb-212, with its short half-life, is advantageously produced closer to the place where it is to be used. Nor is it just a theory. Thor already has a five-year American agreement with RadioMedix, where Thor will supply Th-228 from 2026. RadioMedix specifically needs Th-228 as a precursor for the production of Pb-212 via their generator platform. The same model is seen with other customers. Telix, for example, will use Th-228 from Thor as a precursor for Pb-212 via their own generator and radiopharmacy infrastructure. Therefore, the 300 million NOK are also not presented as financing for a billion-dollar factory in the USA. The capital will, among other things, be used to build downstream Pb-212 capacity and commercial infrastructure in the USA, as well as feedstock and working capital. And regarding the claim of production problems: I cannot find any documentation for it. On the contrary, Thor states that AlphaOne was completed on time and on budget, commercial production has started, the first commercial delivery from AlphaOne has been completed, and production and customer deliveries are now to be gradually increased during ramp-up. This, of course, does not mean that Thor is without risk or will never need more capital. But there is a big difference between that and concluding that they now lack about a billion for an American AlphaTwo factory or have production problems. The actual strategy rather seems to be: produce the longer-lived precursor isotopes centrally and place the short-lived downstream production closer to the customers. In my opinion, this seems much more sensible both industrially and capital-wise.
- ·4 t sittenFinasavisenes' angle: https://e24.no/boers-og-finans/i/6qdy53/thor-medical-truffet-av-emisjonslynet https://www.dn.no/borskommentar/kunne-like-godt-satt-opp-plakat-i-vindu-verdiodeleggende-emisjon-kommer/2-1-2039399 ..That feeling. Buying shares at a price of seven kroner on a Wednesday, and then the share goes on sale at a price of 4.8 kroner the week after...It's always unfortunate when a stock goes down. But I believe the steps they are taking are crucial for future growth. There will probably be new rounds with a need for capital. So if one fears new share issues, TM is not the place to be. But that the company's communication could have been better, I absolutely believe. It is better to inform about growth plans and financing models, than to send some brokerage firms ahead of oneself as useful idiots. That being said, the growth this can generate outweighs the dilution, and that is probably the whole point. To make money. In April, the stock went from 5.5 and for a short while down to the top of the 3-range. It recovers as long as the company delivers on what they say.
- ·21 t sittenThor raised kr 300 mill. That is little. It is not Alpha Two or Alpha Global that are to be built, the gigantic factories will cost approximately kr 1 billion each. So here they will eventually need much more capital. But are they possibly building a US copy of Alpha One over there? I believe the stock price will continue as it is, as they produce far too little from Alpha One. At the Q presentation, the CEO states that they have only delivered th-228 to one customer. Problems with production, or ??Båtsjefen : It's all nonsense you're saying. Read my post and you will understand.
- ·1 päivä sittenDo people think that this is safe in the long term, and will rise higher, and is therefore a good investment?I believe what one will primarily associate this company with in the short and long term is share issues..
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 300 | - | - | ||
| 10 000 | - | - | ||
| 1 517 | - | - | ||
| 3 000 | - | - | ||
| 183 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 -tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 28.8. | ||
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
Välittäjätilasto
Dataa ei löytynyt
2026 H1 -tulosraportti
9 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 -tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 28.8. | ||
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenSome facts about the USA plan and AlphaOne Some things are being mixed up here. Thor has not announced that they are now going to build a new AlphaOne/AlphaTwo factory in the USA for approximately 1 billion NOK. The strategy Thor describes is much more flexible: The central upstream production can continue to be located at Herøya, while downstream production is established closer to customers and patients – among others in the USA. Thor itself writes that the platform can be expanded both through central production and decentralized production closer to the end markets. This makes good sense due to the properties of the isotopes. Th-228 can be produced at Herøya and used as a precursor for Pb-212, while Pb-212, with its short half-life, is advantageously produced closer to the place where it is to be used. Nor is it just a theory. Thor already has a five-year American agreement with RadioMedix, where Thor will supply Th-228 from 2026. RadioMedix specifically needs Th-228 as a precursor for the production of Pb-212 via their generator platform. The same model is seen with other customers. Telix, for example, will use Th-228 from Thor as a precursor for Pb-212 via their own generator and radiopharmacy infrastructure. Therefore, the 300 million NOK are also not presented as financing for a billion-dollar factory in the USA. The capital will, among other things, be used to build downstream Pb-212 capacity and commercial infrastructure in the USA, as well as feedstock and working capital. And regarding the claim of production problems: I cannot find any documentation for it. On the contrary, Thor states that AlphaOne was completed on time and on budget, commercial production has started, the first commercial delivery from AlphaOne has been completed, and production and customer deliveries are now to be gradually increased during ramp-up. This, of course, does not mean that Thor is without risk or will never need more capital. But there is a big difference between that and concluding that they now lack about a billion for an American AlphaTwo factory or have production problems. The actual strategy rather seems to be: produce the longer-lived precursor isotopes centrally and place the short-lived downstream production closer to the customers. In my opinion, this seems much more sensible both industrially and capital-wise.
- ·4 t sittenFinasavisenes' angle: https://e24.no/boers-og-finans/i/6qdy53/thor-medical-truffet-av-emisjonslynet https://www.dn.no/borskommentar/kunne-like-godt-satt-opp-plakat-i-vindu-verdiodeleggende-emisjon-kommer/2-1-2039399 ..That feeling. Buying shares at a price of seven kroner on a Wednesday, and then the share goes on sale at a price of 4.8 kroner the week after...It's always unfortunate when a stock goes down. But I believe the steps they are taking are crucial for future growth. There will probably be new rounds with a need for capital. So if one fears new share issues, TM is not the place to be. But that the company's communication could have been better, I absolutely believe. It is better to inform about growth plans and financing models, than to send some brokerage firms ahead of oneself as useful idiots. That being said, the growth this can generate outweighs the dilution, and that is probably the whole point. To make money. In April, the stock went from 5.5 and for a short while down to the top of the 3-range. It recovers as long as the company delivers on what they say.
- ·21 t sittenThor raised kr 300 mill. That is little. It is not Alpha Two or Alpha Global that are to be built, the gigantic factories will cost approximately kr 1 billion each. So here they will eventually need much more capital. But are they possibly building a US copy of Alpha One over there? I believe the stock price will continue as it is, as they produce far too little from Alpha One. At the Q presentation, the CEO states that they have only delivered th-228 to one customer. Problems with production, or ??Båtsjefen : It's all nonsense you're saying. Read my post and you will understand.
- ·1 päivä sittenDo people think that this is safe in the long term, and will rise higher, and is therefore a good investment?I believe what one will primarily associate this company with in the short and long term is share issues..
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 300 | - | - | ||
| 10 000 | - | - | ||
| 1 517 | - | - | ||
| 3 000 | - | - | ||
| 183 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt